Published in J Psychoactive Drugs on August 23, 2011
Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res (2012) 3.82
Patterns of tobacco use and dual use in US young adults: the missing link between youth prevention and adult cessation. J Environ Public Health (2012) 2.20
Motives, beliefs and attitudes towards waterpipe tobacco smoking: a systematic review. Harm Reduct J (2013) 1.82
Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer Epidemiol Biomarkers Prev (2013) 1.37
The next generation of users: prevalence and longitudinal patterns of tobacco use among US young adults. Am J Public Health (2014) 1.17
The allure of the waterpipe: a narrative review of factors affecting the epidemic rise in waterpipe smoking among young persons globally. Tob Control (2015) 1.11
Facebook Advertisements for Inexpensive Participant Recruitment Among Women in Early Pregnancy. Health Educ Behav (2013) 1.10
Understanding tobacco-related attitudes among college and noncollege young adult hookah and cigarette users. J Am Coll Health (2014) 1.05
Prevalence, knowledge, and practices of hookah smoking among university students, Florida, 2012. Prev Chronic Dis (2014) 0.84
Young adult waterpipe smokers: Smoking behaviors and associated subjective and physiological effects. Addict Behav (2014) 0.81
Abstinence rates among college cigarette smokers enrolled in a randomized clinical trial evaluating Quit and Win contests: The impact of concurrent hookah use. Prev Med (2015) 0.77
Initiation, Progression, and Sustained Waterpipe Use: A Nationally-Representative Longitudinal Study of U.S. Young Adults. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Predictors of intention to quit waterpipe smoking: a survey of arab americans in houston, Texas. J Addict (2015) 0.75
Factors Affecting Hookah Smoking Trend in the Society: A Review Article. Addict Health (2016) 0.75
E-cigarettes: a scientific review. Circulation (2014) 7.99
Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control (2013) 7.69
Metabolism and disposition kinetics of nicotine. Pharmacol Rev (2005) 6.66
Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol (2009) 4.16
Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect (2011) 3.69
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther (2004) 3.49
Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther (2002) 3.36
Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction (2014) 3.00
Formation of carcinogens indoors by surface-mediated reactions of nicotine with nitrous acid, leading to potential thirdhand smoke hazards. Proc Natl Acad Sci U S A (2010) 2.93
Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther (2006) 2.71
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther (2006) 2.49
Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev (2007) 2.43
Active and passive cigarette smoking and acute lung injury after severe blunt trauma. Am J Respir Crit Care Med (2011) 2.39
Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther (2006) 2.35
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev (2012) 2.06
Menthol cigarettes, smoking cessation, atherosclerosis, and pulmonary function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arch Intern Med (2006) 2.01
Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med (2005) 1.94
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90
Electronic cigarettes: a policy statement from the American Heart Association. Circulation (2014) 1.87
Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients. Crit Care Med (2011) 1.86
Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst (2002) 1.83
Mentholated cigarette smoking inhibits nicotine metabolism. J Pharmacol Exp Ther (2004) 1.77
Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res (2003) 1.76
Once-daily dosing of aminoglycosides: how much monitoring is truly required? Am J Med (2003) 1.76
Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther (2006) 1.69
High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation (2004) 1.68
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther (2002) 1.63
Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob Res (2008) 1.62
Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res (2011) 1.61
Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med (2004) 1.57
Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev (2009) 1.53
Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol (2009) 1.52
Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res (2011) 1.50
Salivary cotinine concentration versus self-reported cigarette smoking: Three patterns of inconsistency in adolescence. Nicotine Tob Res (2006) 1.47
Ethnic differences in nicotine metabolic rate among New Zealanders. N Z Med J (2005) 1.46
GHB urine concentrations after single-dose administration in humans. J Anal Toxicol (2006) 1.45
Assessing secondhand smoke using biological markers. Tob Control (2012) 1.44
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics (2005) 1.43
Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther (2006) 1.41
Directly measured secondhand smoke exposure and COPD health outcomes. BMC Pulm Med (2006) 1.39
Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res (2009) 1.36
Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev (2012) 1.34
Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev (2003) 1.32
Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomarkers Prev (2005) 1.31
A genome-wide screen for nicotine dependence susceptibility loci. Am J Med Genet B Neuropsychiatr Genet (2006) 1.25
Interlaboratory comparability of serum cotinine measurements at smoker and nonsmoker concentration levels: a round-robin study. Nicotine Tob Res (2009) 1.21
Longer term exposure to secondhand smoke and health outcomes in COPD: impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Nicotine Tob Res (2009) 1.20
Electronic cigarettes. Cardiology patient page. Circulation (2014) 1.18
Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol (2012) 1.17
Thirdhand smoke causes DNA damage in human cells. Mutagenesis (2013) 1.14
Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions. Br J Clin Pharmacol (2008) 1.14
Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure. Clin Exp Pharmacol Physiol (2005) 1.14
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther (2003) 1.13
Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics (2013) 1.12
Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome. Crit Care Med (2015) 1.10
Estimation of nicotine dose after low-level exposure using plasma and urine nicotine metabolites. Cancer Epidemiol Biomarkers Prev (2010) 1.09
Modeling the relationship of cotinine and self-reported measures of maternal smoking during pregnancy: a deterministic approach. Nicotine Tob Res (2007) 1.09
Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res (2004) 1.08
Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol Biomarkers Prev (2007) 1.06
Clarification of SRNT workgroup guidelines for measures in clinical trials of smoking cessation therapies. Nicotine Tob Res (2004) 1.06
Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev (2003) 1.05
Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev (2010) 1.04
The clinical pharmacology of intranasal l-methamphetamine. BMC Clin Pharmacol (2008) 1.04
Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther (2004) 1.00
Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. Arch Pediatr Adolesc Med (2012) 0.99
Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci (2002) 0.98
CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2007) 0.98
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenet Genomics (2007) 0.97
Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev (2009) 0.97
Short-term metabolic and hemodynamic effects of ephedra and guarana combinations. Clin Pharmacol Ther (2005) 0.95
Exposure to second-hand smoke air pollution assessed from bar patrons' urinary cotinine. Nicotine Tob Res (2006) 0.95
Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine Tob Res (2011) 0.95
Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension (2002) 0.94
Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther (2006) 0.94
Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. Addiction (2012) 0.94
Effect of pregnancy on a measure of FMO3 activity. Br J Clin Pharmacol (2005) 0.94
Vitamin C supplementation decreases oxidative stress biomarker f2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. Nutr Cancer (2003) 0.93
Determinants of salivary cotinine level: a population-based study in Brazil. Rev Saude Publica (2007) 0.92
Environmental and biological monitoring of exposures to PAHs and ETS in the general population. Environ Int (2010) 0.92
Cocaethylene formation following ethanol and cocaine administration by different routes. Exp Clin Psychopharmacol (2011) 0.91
A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenet Genomics (2009) 0.91
Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers. Cancer Epidemiol Biomarkers Prev (2010) 0.91
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics (2007) 0.89
Secondhand smoke exposure in Mexican discotheques. Nicotine Tob Res (2007) 0.89
Beliefs about health, smoking, and future smoking cessation among South Korean men hospitalized for cardiovascular disease. Heart Lung (2007) 0.89
Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob Res (2013) 0.89
Impact of an indoor smoking ban on bar workers' exposure to secondhand smoke. J Occup Environ Med (2009) 0.89
Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev (2012) 0.87
Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum. J Pharmacokinet Pharmacodyn (2002) 0.85
Dietary supplement adverse events: report of a one-year poison center surveillance project. J Med Toxicol (2008) 0.85
Effect of nicotine on cytochrome P450 1A2 activity. Br J Clin Pharmacol (2011) 0.84
Genetic influences on individual differences in nicotine glucuronidation. Twin Res Hum Genet (2009) 0.84
Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. J Anal Toxicol (2004) 0.83